세계의 수막염균 백신 시장 리포트(2023년)

“Meningococcal Vaccines Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on meningococcal vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for meningococcal vaccines? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The meningococcal vaccines market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Vaccine Type: Meningococcal Conjugate Vaccine; Polysaccharide; Subcapsular Vaccine

• 2) By Serotype: Men Acwy; Men B/Bc; Men C

• 3) By Age Group: Infants; Children; Adolescents and Young Adults; Adults

• 4) By Distribution Channel: Pharmacies; Community Clinics; Public Health Agencies; Other Channels

• 5) By End user: Hospitals; Research; Academic Institutes

• Companies Mentioned: Pfizer Inc.; Novartis AG; Sanofi S.A; Serum Institute of India Pvt. Ltd.; GlaxoSmithKline plc

• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

• Time series: Five years historic and ten years forecast.

• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

• Delivery Format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the meningococcal vaccines market are: Pfizer Inc., Novartis AG, Sanofi S.A, Serum Institute of India Pvt. Ltd., GlaxoSmithKline plc, Merck & Co.Inc., Incepta Pharmaceuticals Ltd., Bio-Med Limited, Walvax Biotechnology Co. Ltd., Bio-Manguinhos, Hualan Biological Engineering Inc., JN-International Medical Corporation, Johnson and Johnson, AstraZeneca plc, and Bavarian Nordic A/S.

The global meningococcal vaccines market is expected to grow from $3.21 billion in 2022 to $3.53 billion in 2023 at a compound annual growth rate (CAGR) of 10%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The meningococcal vaccines market is expected to grow to $5.09 billion in 2027 at a CAGR of 9.6%.

The meningococcal vaccines market consists of sales of conjugate vaccines, combination vaccines, serogroup B vaccine products, and other types. Values in this market are 'pharmaceuticals' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Meningococcal vaccinations are vaccines that protect against meningococcal meningitis, an infection with the bacterium Neisseria meningitides that leads to inflammation of the tissues which surround the brain and spinal cord.

North America was the largest region in the meningococcal vaccines market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the meningococcal vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main types of meningococcal vaccines are meningococcal conjugate vaccine, polysaccharide, and subcapsular vaccine. Meningococcal conjugate vaccine refers to a compound made up of a polysaccharide antigen fused (conjugated) to a carrier molecule. The different serotypes include Men Acwy, Men B/Bc, and Men C given to various age groups such as infants, children, adolescents, young adults, and adults distributed by pharmacies, community clinics, public health agencies, and others. These are used by various end-users such as hospitals, research, and academic institutes.

An increase in healthcare spending is expected to propel the growth of the meningococcal vaccine market going forward. Healthcare refers to a residential care institution, nursing facility, intermediate care facility for people with mental illnesses, or intermediate care facility for people with mental retardation. The high expense of new vaccine generations compared to their predecessors has become a key factor in discussions about whether the benefits of the new vaccinations justify their prices. Assessing the complete social and economic advantages of vaccination are becoming an increasingly important area of investigation in the literature on valuing vaccination. For instance, in May 2022, according to an article published by the American Medical Association, a US-based professional association and lobbying group of physicians and medical students, in 2020, healthcare spending in the United States rose by 9.7% to $4.1 trillion, or $12,530 per person. This pace of growth is significantly higher than 2019 (4.3%). Therefore, an increase in healthcare spending is driving the growth of the meningococcal vaccine market.

Product innovation is a key trend in the meningococcal vaccine market. Major players operating in the meningococcal vaccines market are creating innovative new items using cutting-edge technology to maintain their position in the meningococcal vaccines market. For instance, in April 2020, Sanofi Pasteur Inc., a France-based life-protecting vaccines company, received Food and Drug Administration (FDA) approval for the usage of menquadfi by those who are at least 2 years old. Menquadfi helps to prevent the spread of invasive meningococcal illness (including meningitis) caused by the bacteria N meningitides serogroups A, C, W, and Y. The initial and single quadrivalent meningococcal strain is called MenQuadfi vaccination. It employs tetanus toxoid as a protein carrier and is accessible in a ready-to-use liquid format, eliminating the need for healthcare personnel to reconstitute the vaccine.

In August 2022, GlaxoSmithKline plc, a UK-based pharmaceutical and biotechnology company, acquired Affinivax Inc. for $3.3 billion. The acquisition of Affinivax is consistent with GSK's aim of establishing a robust portfolio of specialty medicines and vaccines. Affinivax, Inc., is a US-based next-generation vaccine technology company operating in the meningococcal vaccines market.

The countries covered in the meningococcal vaccines market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The meningococcal vaccines market research report is one of a series of new reports from The Business Research Company that provides meningococcal vaccines market statistics, including meningococcal vaccines industry global market size, regional shares, competitors with a meningococcal vaccines market share, detailed meningococcal vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the meningococcal vaccines industry. This meningococcal vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Table of Contents

1. Executive Summary

2. Meningococcal Vaccines Market Characteristics

3. Meningococcal Vaccines Market Trends And Strategies

4. Meningococcal Vaccines Market - Macro Economic Scenario

• 4.1. COVID-19 Impact On Meningococcal Vaccines Market
• 4.2. Ukraine-Russia War Impact On Meningococcal Vaccines Market
• 4.3. Impact Of High Inflation On Meningococcal Vaccines Market

5. Meningococcal Vaccines Market Size And Growth

• 5.1. Global Meningococcal Vaccines Historic Market, 2017-2022, $ Billion
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints On The Market
• 5.2. Global Meningococcal Vaccines Forecast Market, 2022-2027F, 2032F, $ Billion
  • 5.2.1. Drivers Of The Market
  • 5.2.2. Restraints On the Market

6. Meningococcal Vaccines Market Segmentation

• 6.1. Global Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Meningococcal Conjugate Vaccine
• Polysaccharide
• Subcapsular Vaccine
• 6.2. Global Meningococcal Vaccines Market, Segmentation By Serotype, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Men Acwy
• Men B/Bc
• Men C
• 6.3. Global Meningococcal Vaccines Market, Segmentation By Age Group, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Infants
• Children
• Adolescents and Young Adults
• Adults
• 6.4. Global Meningococcal Vaccines Market, Segmentation By Distribution Channel:, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Pharmacies
• Community Clinics
• Public Health Agencies
• Other Channels
• 6.5. Global Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Hospitals
• Research
• Academic Institutes

7. Meningococcal Vaccines Market Regional And Country Analysis

• 7.1. Global Meningococcal Vaccines Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 7.2. Global Meningococcal Vaccines Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

8. Asia-Pacific Meningococcal Vaccines Market

• 8.1. Asia-Pacific Meningococcal Vaccines Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 8.3. Asia-Pacific Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

9. China Meningococcal Vaccines Market

• 9.1. China Meningococcal Vaccines Market Overview
• 9.2. China Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
• 9.3. China Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

10. India Meningococcal Vaccines Market

• 10.1. India Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 10.2. India Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

11. Japan Meningococcal Vaccines Market

• 11.1. Japan Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 11.2. Japan Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

12. Australia Meningococcal Vaccines Market

• 12.1. Australia Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 12.2. Australia Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

13. Indonesia Meningococcal Vaccines Market

• 13.1. Indonesia Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 13.2. Indonesia Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

14. South Korea Meningococcal Vaccines Market

• 14.1. South Korea Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 14.2. South Korea Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

15. Western Europe Meningococcal Vaccines Market

• 15.1. Western Europe Meningococcal Vaccines Market Overview
• 15.2. Western Europe Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 15.3. Western Europe Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

16. UK Meningococcal Vaccines Market

• 16.1. UK Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 16.2. UK Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

17. Germany Meningococcal Vaccines Market

• 17.1. Germany Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 17.2. Germany Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

18. France Meningococcal Vaccines Market

• 18.1. France Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 18.2. France Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

19. Eastern Europe Meningococcal Vaccines Market

• 19.1. Eastern Europe Meningococcal Vaccines Market Overview
• 19.2. Eastern Europe Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 19.3. Eastern Europe Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

20. Russia Meningococcal Vaccines Market

• 20.1. Russia Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 20.2. Russia Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

21. North America Meningococcal Vaccines Market

• 21.1. North America Meningococcal Vaccines Market Overview
• 21.2. North America Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 21.3. North America Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

22. USA Meningococcal Vaccines Market

• 22.1. USA Meningococcal Vaccines Market Overview
• 22.2. USA Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 22.3. USA Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

23. South America Meningococcal Vaccines Market

• 23.1. South America Meningococcal Vaccines Market Overview
• 23.2. South America Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 23.3. South America Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

24. Brazil Meningococcal Vaccines Market

• 24.1. Brazil Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 24.2. Brazil Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

25. Middle East Meningococcal Vaccines Market

• 25.1. Middle East Meningococcal Vaccines Market Overview
• 25.2. Middle East Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 25.3. Middle East Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

26. Africa Meningococcal Vaccines Market

• 26.1. Africa Meningococcal Vaccines Market Overview
• 26.2. Africa Meningococcal Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 26.3. Africa Meningococcal Vaccines Market, Segmentation By End user, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

27. Meningococcal Vaccines Market Competitive Landscape And Company Profiles

• 27.1. Meningococcal Vaccines Market Competitive Landscape
• 27.2. Meningococcal Vaccines Market Company Profiles
  • 27.2.1. Pfizer Inc
    • 27.2.1.1. Overview
    • 27.2.1.2. Products and Services
    • 27.2.1.3. Strategy
    • 27.2.1.4. Financial Performance
  • 27.2.2. Novartis AG
    • 27.2.2.1. Overview
    • 27.2.2.2. Products and Services
    • 27.2.2.3. Strategy
    • 27.2.2.4. Financial Performance
  • 27.2.3. Sanofi S.A
    • 27.2.3.1. Overview
    • 27.2.3.2. Products and Services
    • 27.2.3.3. Strategy
    • 27.2.3.4. Financial Performance
  • 27.2.4. Serum Institute of India Pvt. Ltd
    • 27.2.4.1. Overview
    • 27.2.4.2. Products and Services
    • 27.2.4.3. Strategy
    • 27.2.4.4. Financial Performance
  • 27.2.5. GlaxoSmithKline plc
    • 27.2.5.1. Overview
    • 27.2.5.2. Products and Services
    • 27.2.5.3. Strategy
    • 27.2.5.4. Financial Performance

28. Key Mergers And Acquisitions In The Meningococcal Vaccines Market

29. Meningococcal Vaccines Market Future Outlook and Potential Analysis

30. Appendix

• 30.1. Abbreviations
• 30.2. Currencies
• 30.3. Historic And Forecast Inflation Rates
• 30.4. Research Inquiries
• 30.5. The Business Research Company
• 30.6. Copyright And Disclaimer